1980 related articles for article (PubMed ID: 26298664)
1. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
[TBL] [Abstract][Full Text] [Related]
4. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
6. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in the association between AD biomarkers and cognitive decline.
Koran MEI; Wagener M; Hohman TJ;
Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
[TBL] [Abstract][Full Text] [Related]
8. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
[TBL] [Abstract][Full Text] [Related]
9. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
10. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
Skouras S; Torner J; Andersson P; Koush Y; Falcon C; Minguillon C; Fauria K; Alpiste F; Blenow K; Zetterberg H; Gispert JD; Molinuevo JL;
Brain; 2020 Mar; 143(3):976-992. PubMed ID: 32091109
[TBL] [Abstract][Full Text] [Related]
11. The relationship between APOE genotype, CSF Tau and cognition across the Alzheimer's disease spectrum, moderation and mediation role of insula network connectivity.
Zhu Y; Wu Y; Lv X; Wu J; Shen C; Tang Q; Wang G;
CNS Neurosci Ther; 2024 Jan; 30(1):e14401. PubMed ID: 37577852
[TBL] [Abstract][Full Text] [Related]
12. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
13. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
14. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
[TBL] [Abstract][Full Text] [Related]
16. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
17. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
Bonham LW; Desikan RS; Yokoyama JS;
Acta Neuropathol Commun; 2016 Jun; 4(1):65. PubMed ID: 27357286
[TBL] [Abstract][Full Text] [Related]
18. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic functional connectivity alterations in cognitively intact elderly APOE ε4 carriers measured by eigenvector centrality mapping are related to cognition and CSF biomarkers: a preliminary study.
Luo X; Qiu T; Jia Y; Huang P; Xu X; Yu X; Shen Z; Jiaerken Y; Guan X; Zhou J; Zhang M;
Brain Imaging Behav; 2017 Oct; 11(5):1290-1301. PubMed ID: 27714554
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
